Quarterly revenue details

■Revenue by business segment (JPY mill											
	FY2021						FY2022				
	Q1	Q2	Q3	Q4	Full	Q1	Q2	Q3	Q4	Full	Full Forecast
Prescription pharmaceuticals	61,008	59,363	62,576	66,633	249,579	61,105		-			244,400
YoY	12.3%	3.9%	6.0%	3.8%	6.3%	0.2%					-2.1%
OTC pharmaceuticals	2,444	2,643	2,655	2,038	9,780	2,379					10,650
YoY	19.7%	-10.8%	11.5%	0.7%	3.9%	-2.7%					8.9%
Medical devices	1,145	1,337	1,371	1,332	5,184	1,624					7,202
Others	389	431	441	453	1,714	425					1,748
Total	64,986	63,773	67,042	70,456	266,257	65,533					264,000
YoY	12.9%	4.0%	6.6%	3.9%	6.7%	0.8%					-0.8%

[Japan] (JPY million												
		FY2021					FY2022					
	Q1	Q2	Q3	Q4	Full	Q1	Q2	Q2 Q3	Q4	Full	Full	
	Qı	QZ	Q3	Q4 	ı uli	Q I	QZ	Q3	Q4	Full	Forecast	
Prescription pharmaceuticals	38,952	36,723	40,097	43,933	159,705	38,839					141,700	
YoY	11.0%	1.8%	2.8%	-3.8%	2.5%	-0.3%					-11.3%	
OTC pharmaceuticals	2,305	2,486	2,490	1,904	9,185	2,141					9,400	
YoY	16.7%	-12.8%	8.1%	-1.2%	1.4%	-7.1%					2.3%	
Medical devices	695	847	767	830	3,139	890					3,400	
Others	369	401	428	407	1,604	408					1,500	
Total	42,321	40,456	43,782	47,074	173,633	42,279					156,000	
YoY	11.3%	1.3%	3.2%	-3.4%	2.7%	-0.1%					-10.2%	

[Overseas]										(JPY	millions)		
		FY2021						FY2022					
	Q1	Q2	Q3	Q4	Full	Q1	Q2	Q3	Q4	Full	Full		
	3	QZ_	QU	Q+	i uli	Q I	QZ	QU	Q+	ı uıı	Forecast		
Prescription pharmaceuticals	22,055	22,640	22,479	22,699	89,874	22,266					102,700		
YoY	14.5%	7.4%	12.2%	22.6%	13.9%	1.0%					14.3%		
OTC pharmaceuticals	139	157	165	134	595	238					1,250		
YoY	106.3%	43.0%	109.5%	39.5%	69.1%	71.1%					110.2%		
Medical devices	450	489	604	502	2,046	733					3,802		
Others	20	30	13	46	109	18					248		
Total	22,665	23,317	23,261	23,382	92,624	23,255					108,000		
YoY	15.9%	8.9%	13.8%	22.6%	15.1%	2.6%				,	16.6%		

■Revenue by region										(JPY	millions)		
		FY2021						FY2022					
	Q1	Q2	Q3	Q4	Full	Q1	Q2	Q2 Q3	Q4	Full	Full		
	Q I	QZ		Q+	ı uli	QΊ	QZ	Q0	Q+	i uli	Forecast		
China	6,460	7,556	6,329	6,852	27,197	3,630					35,000		
YoY	11.2%	8.7%	13.6%	36.5%	16.5%	-43.8%					28.7%		
Asia (Not Including China)	4,600	4,457	4,641	6,115	19,813	5,680					23,000		
YoY	16.4%	-15.0%	12.7%	56.7%	15.1%	23.5%					16.1%		
EMEA	10,704	10,538	11,572	10,085	42,899	13,062					45,500		
YoY	11.9%	19.0%	15.5%	6.7%	13.2%	22.0%					6.1%		
Americas	901	766	718	330	2,715	882					4,500		
YoY	305.8%	117.3%	-2.4%	-52.9%	35.0%	-2.1%					65.8%		

Quarterly revenue details

■Revenue of major products (JPY millions) FY2021 FY2022 FY2022 Brand name Full Ω1 Ω2 Q3 Q4 Full Q1 Ω2 Q3 Q4 Full Forecast Glaucoma and ocular hypertension 5,437 5,321 5,638 5,355 21,752 6,030 21,523 1,576 1,442 1,523 1,108 5,650 1,434 4,898 Japan Cosopt 1,240 1,223 1,347 1,347 5,157 1,460 5,630 Asia 3,137 EMEA 2,621 2,656 2,769 2,900 10,945 10,995 4,683 4,503 4,860 4,378 18,423 4,895 19,705 Total 2,281 2,118 2,256 1,755 8,409 2,275 7,847 Japan Tapros 266 199 258 448 1,170 126 2,740 China 490 493 518 576 2 077 516 2 051 Asia 1,646 1,693 1,828 1,599 6,767 1,978 7,067 EMEA 1,747 1,693 1,904 1,627 6,971 2,129 7,577 Total 724 688 744 582 2,738 2,628 760 Japan **Tapcom** 209 Asia 173 202 231 815 240 964 EMEA 850 803 951 814 3,417 1,129 3,985 1,169 4,224 1,123 1,130 Total 951 4,374 1,251 310 278 300 221 1,108 965 Japan 294 Trusopt 92 102 84 104 382 98 413 Asia 768 743 746 626 2,883 859 2,847 EMEA 803 823 848 946 3.420 1.123 4 030 Total Eybelis 806 822 912 763 3.304 3.648 1,076 Japan 47 Asia 17 25 33 40 116 332 Dry Eye 4,537 4,649 5,063 4,586 18,835 5,069 24,422 Total 3 402 3,249 3 662 3 029 15,157 13.342 3,876 Japan Diquas 697 983 958 1,435 4,074 666 6,964 China 438 417 443 121 1,419 527 2,301 Asia 4,251 4,063 4,933 4,532 17,779 3,303 17,235 Total 1,347 1,721 1,602 1.797 6.466 1,636 5,115 Japan Hyalein 2,145 2,074 2,731 1,993 8,943 875 9,344 China 386 2.370 793 2.776 387 405 1 192 Asia 1,656 1,356 1,641 1,204 5,856 1,817 6,667 Total Ikervis 1,506 246 291 276 294 1.106 357 Asia 1,410 1,065 1,365 910 1,460 EMEA 4,750 5,161 1.099 829 806 902 693 3,230 3,785 Total 103 82 173 109 467 121 406 Asia Cationorm 707 **EMEA** 532 536 563 448 2,078 2,458 194 188 165 137 685 271 920 America Allergy 4,502 5,065 4,900 14,925 29,392 4,846 24,074 Total Alesion 5,038 4,468 4,880 14,900 29,286 4,798 23,821 Japan (Including Alesion LX) 28 34 20 25 106 48 253 Asia 164 149 151 169 633 213 1,588 Total Verkazia 155 137 159 585 157 743 **EMEA** 133 10 12 10 49 56 792 18 merica Intravitreal VEGF inhibitor 18,727 17,748 19,451 16,558 72,484 18,230 61,896 Total EYLEA *1 18,727 17,748 19,451 16,558 72,484 18,230 61,896 Japan Bacterial conjunctivitis 3,063 3,797 2,282 11,852 2,570 11,712 1,926 Total 488 483 469 314 1.754 378 1.489 Japan Cravit 1,754 2,661 1,144 1,406 6,966 727 7,195 China 505 369 355 637 1.866 476 2.056 Asia 316 283 314 213 1,126 345 1,112 **EMEA** Medical devices 341 327 391 363 1,422 331 1,742 Total Lentis comfort 341 327 391 363 1,422 331 1.742 Japan 347 381 439 445 1,612 627 2,398 Total PRESERFLO MicroShunt EMEA 347 381 439 445 1,612 627 2,364 Total 2.444 2.643 2,655 2,038 9,780 2,379 10,650 2,486 9,400 2,305 2,490 1,904 9,185 2,141 Japan OTC pharmaceuticals 31 650 China 139 157 207 165 127 588 Asia

¹ Co-promoted product of Bayer Yakuhin, Ltd. (MAH)

^{*}Forecasts in this report are based on currently available information. Actual results may differ materially depending on a number of factors including business environment change and others. Our full-year forecasts are based on our foreign exchange assumptions. Revenue by region shows that of major countries or regions.